Oljacic S - Search Results

1

Discovery of (3-Phenylcarbamoyl-3,4-dihydro-2H-pyrrol-2-yl)phosphonates as Imidazoline I₂ Receptor Ligands with Anti-Alzheimer and Analgesic Properties.

Bagán A, López-Ruiz A, Abás S, Ruiz-Cantero MC, Vasilopoulou F, Taboada-Jara T, Griñán-Ferré C, Pallàs M, Muguruza C, Diez-Alarcia R, Callado LF, Entrena JM, Cobos EJ, Pérez B, Morales-García JA, Molins E, De Jonghe S, Daelemans D, Brea J, Val C, Loza MI, Hernández-Hernández E, García-Sevilla JA, García-Fuster MJ, Díaz C, Fernández-Godino R, Genilloud O, Beljkaš M, Oljačić S, Nikolic K, Escolano C. Bagán A, et al. Among authors: oljacic s. J Med Chem. 2025 Jan 17. doi: 10.1021/acs.jmedchem.4c01644. Online ahead of print. J Med Chem. 2025. PMID: 39818939

2

Modelling of chromatographic and electrophoretic behaviour of imidazoline and alpha adrenergic receptors ligands under different acid-base conditions.

Oljacic S, Križman M, Popovic-Nikolic M, Vovk I, Nikolic K, Agbaba D. Oljacic S, et al. ADMET DMPK. 2024 May 3;12(5):737-757. doi: 10.5599/admet.2278. eCollection 2024. ADMET DMPK. 2024. PMID: 39524217 Free PMC article.

3

Computer-aided Drug Discovery of Epigenetic Modulators in Dual-target Therapy of Multifactorial Diseases.

Oljacic S, Popovic Nikolic M, Filipic B, Gagic Z, Nikolic K. Oljacic S, et al. Curr Top Med Chem. 2024 Nov 4. doi: 10.2174/0115680266337668241025061804. Online ahead of print. Curr Top Med Chem. 2024. PMID: 39501944

4

Development of Novel ROCK Inhibitors via 3D-QSAR and Molecular Docking Studies: A Framework for Multi-Target Drug Design.

Beljkas M, Petkovic M, Vuletic A, Djuric A, Santibanez JF, Srdic-Rajic T, Nikolic K, Oljacic S. Beljkas M, et al. Among authors: oljacic s. Pharmaceutics. 2024 Sep 26;16(10):1250. doi: 10.3390/pharmaceutics16101250. Pharmaceutics. 2024. PMID: 39458584 Free PMC article.

5

Evaluation of novel compounds as anti-bacterial or anti-virulence agents.

Filipić B, Ušjak D, Rambaher MH, Oljacic S, Milenković MT. Filipić B, et al. Among authors: oljacic s. Front Cell Infect Microbiol. 2024 Mar 6;14:1370062. doi: 10.3389/fcimb.2024.1370062. eCollection 2024. Front Cell Infect Microbiol. 2024. PMID: 38510964 Free PMC article. Review.

6

Targeting Histone Deacetylases 6 in Dual-Target Therapy of Cancer.

Beljkas M, Ilic A, Cebzan A, Radovic B, Djokovic N, Ruzic D, Nikolic K, Oljacic S. Beljkas M, et al. Among authors: oljacic s. Pharmaceutics. 2023 Nov 3;15(11):2581. doi: 10.3390/pharmaceutics15112581. Pharmaceutics. 2023. PMID: 38004560 Free PMC article. Review.

7

Preclinical Evaluation of an Imidazole-Linked Heterocycle for Alzheimer's Disease.

Bagán A, Rodriguez-Arévalo S, Taboada-Jara T, Griñán-Ferré C, Pallàs M, Brocos-Mosquera I, Callado LF, Morales-García JA, Pérez B, Diaz C, Fernández-Godino R, Genilloud O, Beljkas M, Oljacic S, Nikolic K, Escolano C. Bagán A, et al. Among authors: oljacic s. Pharmaceutics. 2023 Sep 25;15(10):2381. doi: 10.3390/pharmaceutics15102381. Pharmaceutics. 2023. PMID: 37896141 Free PMC article.

8

The evaluation of drug-plasma protein binding interaction on immobilized human serum albumin stationary phase, aided by different computational approaches.

Obradović D, Radan M, Đikić T, Nikolić MP, Oljačić S, Nikolić K. Obradović D, et al. Among authors: oljacic s. J Pharm Biomed Anal. 2022 Mar 20;211:114593. doi: 10.1016/j.jpba.2022.114593. Epub 2022 Jan 14. J Pharm Biomed Anal. 2022. PMID: 35086032

9

Synthesis, in silico, and in vitro studies of novel dopamine D₂ and D₃ receptor ligands.

Elek M, Djokovic N, Frank A, Oljacic S, Zivkovic A, Nikolic K, Stark H. Elek M, et al. Among authors: oljacic s. Arch Pharm (Weinheim). 2021 Jun;354(6):e2000486. doi: 10.1002/ardp.202000486. Epub 2021 Feb 22. Arch Pharm (Weinheim). 2021. PMID: 33615541

10

Quantitative structure-activity relationships of xanthen-3-one and xanthen-1,8-dione derivatives and design of new compounds with enhanced antiproliferative activity on HeLa cervical cancer cells.

Zukić S, Oljacic S, Nikolic K, Veljović E, Špirtović-Halilović S, Osmanović A, Završnik D. Zukić S, et al. Among authors: oljacic s. J Biomol Struct Dyn. 2021 Jul;39(11):4026-4036. doi: 10.1080/07391102.2020.1775125. Epub 2020 Jun 11. J Biomol Struct Dyn. 2021. PMID: 32462973

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

12 results

Search Page

Filters